WASHINGTON, DC - AUGUST 31: U.S. President Donald Trump, accompanied by (L-R) B1 Medicines CEO John Oiler, Astellas Pharma President Michael Putrasis, Commerce Secretary Howard Lutnick, Health and Human Services Secretary Robert F. Kennedy Jr., and Administrator for the Centers for Medicare & Medicaid Services Dr. Mehmet Oz, holds up a poster that displays drug prices as he speaks during a healthcare affordability event in the Oval Office at the White House on August 31, 2026 in Washington, DC. President Trump announced that nearly a dozen pharmaceutical manufacturers have agreed to lower the price of their medications to match their prices outside of the United States. (Credit: Photo by Kevin Dietsch/Getty Images)
President Trump's "most-favored-nation" pricing push added nine more pharmaceutical companies this week, bringing the roster of participants to 26. But independent reporting shows several of the administration's dollar figures rest on shakier assumptions than the topline numbers suggest, and the Medicaid channel that carries the discounts skips over millions of Latino families in Texas and Florida who never got Medicaid expansion.
A ninth round, and a familiar promise
Sign up to read this article
Read news from 100's of titles, curated specifically for you.
